Arcus Biosciences, Inc. (RCUS) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Arcus Biosciences is a clinical-stage biopharmaceutical company focused on immuno-oncology. The company has no approved products and generates revenue primarily through collaboration agreements, most notably with Gilead Sciences, Inc. As of September 30, 2025, the company had 107.97 million shares of common stock outstanding.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenues | $26 million | $48 million | $214 million | $232 million |
| Net Loss | $(135) million | $(92) million | $(247) million | $(189) million |
| Net Loss Per Share (Basic/Diluted) | $(1.27) | $(1.00) | $(2.39) | $(2.11) |
| Research & Development Expenses | $141 million | $123 million | $402 million | $347 million |
| Cash, Cash Equivalents & Marketable Securities | $841 million | $992 million (Dec 31, 2024) | N/A | N/A |
| Long-Term Debt | $98 million | $48 million (Dec 31, 2024) | N/A | N/A |
Note: Revenue figures include significant non-cash adjustments related to contract modifications. Operating cash flow for the nine months ended September 30, 2025, was a use of $362 million.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 46% in Q3 2025 compared to Q3 2024. This was driven by the absence of a $15 million license revenue from Taiho recognized in the prior year and lower development service revenues from Gilead.
- Contract Modification Impact: In Q2 2025, Gilead terminated its rights to the etrumadenant program. This triggered a contract modification accounting treatment, resulting in a $143 million cumulative catch-up revenue recognized in the nine months ended September 30, 2025. Without this adjustment, the net loss would have been significantly higher.
- Increased R&D Spend: R&D expenses increased 15% in Q3 2025 and 16% for the nine-month period, primarily due to increased enrollment and start-up activities for late-stage programs (PRISM-1 and PEAK-1).
- Debt Expansion: Long-term debt increased from $48 million to $98 million due to an additional $50 million draw on the Hercules Capital term loan facility in Q2 2025.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management believes current cash and marketable securities ($841 million) are sufficient to fund operations for at least twelve months and through initial pivotal read-outs for domvanalimab, quemliclustat, and casdatifan. The company expects R&D expenses to decline in Q4 2025 as costs for the domvanalimab Phase 3 program decrease.
Key Developments:
- Casdatifan (HIF-2α): Taiho exercised its option for exclusive license in Japan in October 2025. New Phase 1/1b data showed a 31% confirmed overall response rate in late-line metastatic kidney cancer.
- Domvanalimab (TIGIT): First overall survival results from the EDGE-Gastric study showed a median OS of 26.7 months.
- Quemliclustat (CD73): Enrollment for the Phase 3 PRISM-1 trial in pancreatic cancer was completed within 12 months of initiation.
- Study Pause: The eVOLVE-RCC02 study (casdatifan + volrustomig) paused recruitment in October 2025 to monitor potentially immune-mediated adverse events, though no Grade 4 or 5 events were observed.
Risks and Contingencies:
- Capital Requirements: The company has a history of operating losses and an accumulated deficit of $1.38 billion. Additional funding will be required to sustain long-term development.
- Regulatory and Clinical Risk: Success depends on regulatory approval of investigational products. Clinical trial results are not guaranteed, and the company faces risks related to enrollment, safety signals, and the complexity of combination therapies.
- Third-Party Reliance: Heavy reliance on Gilead for commercialization and third-party manufacturers (e.g., WuXi Biologics in China) for supply creates operational and geopolitical risks.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of revenue streams given the $143 million one-time catch-up adjustment and the termination of the etrumadenant program.
- Cash Burn Rate: Assess the runway provided by the $841 million cash balance against the $362 million operating cash burn in the first nine months of 2025.
- Clinical Milestones: Monitor the resolution of the eVOLVE-RCC02 study pause and the upcoming readouts for PRISM-1 and PEAK-1.
- Debt Covenants: Review the terms of the Hercules Capital loan, specifically the interest-only period and payment-in-kind (PIK) interest election.
- Collaboration Terms: Confirm the status of Gilead's option rights for remaining programs and the financial implications of the Taiho option exercise for casdatifan.